Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jan;69(1):29-38.
doi: 10.1007/s00251-016-0949-3. Epub 2016 Aug 26.

A novel deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype

Affiliations
Case Reports

A novel deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype

Wenjun Mou et al. Immunogenetics. 2017 Jan.

Abstract

Severe combined immunodeficiency (SCID) is the most serious disorder among primary immunodeficiency diseases threatening children's life. Atypical SCID variant, presenting with mild reduced T cells subsets, is often associated with infection susceptibility but poor clinical diagnosis. The atypical X-SCID patient in the present study showed a mild clinical presentation with a TlowNK+B+ immunophenotype. The patient has reduced T- cell subpopulations with a subdued thymic output measured by sjTRECs. Further analysis showed that T cells maintained a normal proliferation and a broad Vβ repertoire. NK cells, however, exhibited a skewed development toward immature CD3-CD16+CD56- cells. Genetic analysis revealed a novel deletion at nucleotide 52 in exon 1 of IL2RG gene. Sequence alignment predicted a truncated IL2RG protein missing signal peptide derived from a possible alternative reading frame. The novel mutation in IL2RG gene identified in our study may help the early diagnosis of atypical X-SCID.

Keywords: Atypical SCID; Frameshift; IL2RG gene; Primary immunodeficiency diseases; Signal peptide; X-linked SCID.

PubMed Disclaimer

References

    1. J Clin Immunol. 2015 May;35(4):416-30 - PubMed
    1. Methods Enzymol. 1996;266:383-402 - PubMed
    1. Clin Immunol. 2011 Oct;141(1):73-82 - PubMed
    1. J Immunol. 2001 Jul 1;167(1):1-5 - PubMed
    1. Immunol Rev. 2004 Dec;202:67-83 - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources